Search Within

Alison Michele Schram

Formats
  1. Meeting Abstract (59)
  2. Journal Article (57)
  3. Editorial (3)
  4. Review (3)
  5. Miscellaneous (2)
  6. Research Letter (1)
Groups
  1. Department of Medicine (125)
  2. Early Drug Development Service (125)
  3. Gynecologic Medicine Service (125)
  4. Solid Tumor Oncology Division (125)
  5. GSK Faculty (53)
  6. Thoracic Oncology (50)

More Groups

People
  1. David Hyman (49)
  2. Alexander Drilon (46)
  3. Michael Berger (23)
  4. Barry Taylor (16)
  5. Marc Ladanyi (16)
  6. Helen Won (14)

More People

Years
  1. 2025 (7)
  2. 2024 (18)
  3. 2023 (9)
  4. 2022 (16)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (13)
  3. Cancer Research (13)
  4. Cancer Discovery (9)
  5. Clinical Cancer Research (5)
  6. JCO Precision Oncology (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. American Association for Cancer Research (30)
  3. Oxford University Press (14)
  4. Nature Publishing Group (12)
  5. Elsevier Inc. (10)
  6. American Medical Association (3)

More Publishers

Results (125)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
    Meeting Abstract

    Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study
    Meeting Abstract

    Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • The use of zenocutuzumab for NRG1 fusion–positive tumors [Interview]
    Miscellaneous

    Schram, A.
    Clinical Advances in Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Emerging tumor-agnostic molecular targets
    Review

    Bhamidipati, D.; Schram, A. M.
    Molecular Cancer Therapeutics (2024)

    Fulltext@MSK | Save
  • The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): A tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
    Journal Article

    Westphalen, C. B.; Martins-Branco, D.; Beal, J. R.; Cardone, C.; Coleman, N.; Schram, A. M.; Halabi, S.; Michiels, S.; Yap, C.; André, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Basket trials: Past, present, and future
    Review

    Murciano-Goroff, Y. R.; Uppal, M.; Chen, M.; Harada, G.; Schram, A. M.
    Annual Review of Cancer Biology (2024)

    Fulltext@MSK | Save
  • The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
    Journal Article

    Kim, D. W.; Schram, A. M.; Hollebecque, A.; Nishino, K.; Macarulla, T.; Rha, S. Y.; Duruisseaux, M.; Liu, S. V.; Al Hallak, M. N.; Umemoto, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Defining a space for NRG1 fusion-positive tumors in lung and GI cancers
    Miscellaneous

    Spira, A. I.; Macarulla, T.; Neuzillet, C.; Sabari, J. K.; Schram, A.; Van Cutsem, E.
    Oncology (Norwalk) (2024)

    Fulltext@MSK | Save